|
Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform. |
| |
|
Consulting or Advisory Role - Bayer/Onyx; Merck; Newlink Genetics |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Novartis (Inst); Taiho Pharmaceutical |
| |
|
Honoraria - American College of Surgeons |
Consulting or Advisory Role - American College of Surgeons |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Patents, Royalties, Other Intellectual Property - NSABP Foundation (Inst) |
| |
|
Consulting or Advisory Role - Bayer |
|
| |
|
Research Funding - Abbvie (Inst) |